迪生力(603335.SH):擬對廣東威瑪增資5665萬元
格隆匯7月23日丨迪生力(603335.SH)公佈,公司子公司廣東威瑪經過上半年的工藝測試已完成,目前準備進入全面生產階段,需要完善生產線的設備及流動資金的補充,使項目儘快走入正常運營,提高公司的市場競爭實力,加強廣東威瑪的抗風險能力,經廣東威瑪股東一致同意,廣東威瑪增加註冊資本人民幣1.03億元,增資後廣東威瑪的註冊資本由人民幣1.8億元增至人民幣2.83億元。
公司擬以貨幣方式認繳增資額5665萬元,韶關中弘以設備作價方式認繳增資額4635萬元,韶關中達放棄增資優先認繳權。此次增資後公司仍持有廣東威瑪55%股權,公司合併報表範圍不會發生變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.